The global market for connected insulin pens could be worth up to $123 million by 2023, according to a report published this year by Research & Markets.
Insulin pens, designed for people who control their diabetes with multiple daily injections instead of a pump or wearable patch, are portable devices that were first introduced in 1985 with Novo Nordisk‘s (NYSE:NVO) NovoPen. Since then, technology has evolved to allow users to track their insulin usage, set reminders and alarms, as well as share their data with caregivers and doctors. Here’s a look at some of the key players shaping the future of connected insulin pens.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.